Project Details
Description
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.
| Acronym | PIONEER 4 |
|---|---|
| Status | Finished |
| Effective start/end date | 10/08/16 → 30/03/18 |
Collaborative partners
- Novo Nordisk (lead)
- Emirates Health Services
- Abu Dhabi Health Services Company
Keywords
- Metabolic Diseases
- Glucose Metabolism Disorders
- Endocrine System Diseases
- Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Glucagon-Like Peptide-1 Receptor Agonists
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Incretins
- Hormones
- Hormone Substitutes
- Hormone Antagonists
- Semaglutide
- Liraglutide
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.